 |
Interleukin-2 (IL-2) As Immune-Based Therapy For HIV
An important article in the July 12 issue of the Journal of the
American Medical Association (JAMA) by Dr. Richard T.
Davey, Jr., of the National Institute of Allergy and
Infectious Diseases (NIAID) and colleagues heralds a series
of anticipated papers and presentations over the coming
months. All will report new data on the potential role of
interleukin-2 (IL-2) in treating people with HIV infection.
An immune-based therapy, IL-2 is a laboratory-engineered
product modeled after a substance the body makes that
promotes T-cell growth.
More...
|
|
 |
IL-2 Information At The NIH
Clinicians interested in the clinical trials regarding Interleukin-2 can use this list of links to a variety of sites at the NIH to study the trials in greater detail. Most of the trials are concluded and their summaries are posted in this list. The Interleukin-2 and HIV trials will be in the news in the coming months as information from the world-wide AIDS conference in South Africa is released.
More...
|
|
 |
Interleukin-2 Information For Patients
Newly released clinical trials involving the use of IL-2 in HIV infected patients will increase the demand for information on the drug. Vidyya presents this fact sheet on IL-2 for the use of your patients. More...
|
|
 |
Nationwide Recall Of Sangcya Oral Solution
The Food and Drug Administration today announced the nationwide recall of SangCya oral solution, a generic version of the anti-rejection drug cyclosporine (Neoral oral solution), because of clinical evidence that the generic drug's availability is reduced relative to Neoral oral solution if the drug is administered with apple juice. Patients taking cyclosporine capsules are not affected by this recall.
More... |
|